Results 251 to 260 of about 119,989 (312)

Molecular subtyping and precision therapy for esophageal cancer

Interdisciplinary Medicine, EarlyView.
The molecular typing of esophageal cancer based on genome, transcriptome, proteome, and multi‐omics revealed various molecular features and provided potential targets for the precision therapy. Recent trials have shown that immunotherapy or molecular targeted therapy plus chemoradiotherapy can improve overall survival and progression‐free survival in ...
Guangkun Pei, Zhuoran Liang, Bianli Gu, Linlin Shi, Ze‐Xian Liu, Shegan Gao   +5 more
wiley   +1 more source

Ex vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a phase I/II pilot study. [PDF]

Cancer Immunol Immunother
Rostami T, Ahmadvand M, Azari M, Kasaeian A, Chahardouli B, Shemshadi Nia MR, Azari M, Rostami MR, Ahangar-Sirous R, Kiumarsi A, Janbabai G.   +10 more
europepmc   +1 more source

Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives

Interdisciplinary Medicine, EarlyView.
Infographics of this review introducing the current treatment strategies, types of nanomaterials, and their advantages in AML treatment (Created with BioRender.com, a license purchased, accessed on March 26, 2024). Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates ...
Jiarui Zhao, Jiaqi Cui, Lixuan Wang, Xinyi Shi, Jiayan Ding, Muhammad Farhan Sohail, Irshad Hussain, Qihui Liu, Fangfang Chen   +8 more
wiley   +1 more source

Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy. [PDF]

Front Immunol
Wei J, Li D, Long H, Han M.
europepmc   +1 more source

Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine

Interdisciplinary Medicine, EarlyView.
Novel biomarker emergence plays a critical role in improving CHB management. Advances in sensitive detection methods, AI, and large‐scale data platforms have independently contributed to biomarkers while driving the development of multi‐omics approaches.
Yaru Shi, Rong Fan
wiley   +1 more source

Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors. [PDF]

Int J Mol Sci
Choi Y, Tan J, Lin D, Lee JS, Yuan Y.
europepmc   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, EarlyView.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions. [PDF]

Front Oncol
Ruan L, Wang L.
europepmc   +1 more source

Exploring the Role of T‐Cell Metabolism in Modulating Immunotherapy Efficacy for Non‐Small Cell Lung Cancer Based on Clustering

Journal of Clinical Laboratory Analysis, EarlyView.
We conducted a comprehensive investigation of the metabolic profiles of infiltrating T cells in NSCLC tumors and found metabolic heterogeneity in three T‐cell subtypes, which are associated with the prognosis of ICB therapy. We defined these metabolic clusters as response‐dependent (R) clusters and non‐response‐dependent (NR) clusters, and elucidated ...
Hongzhe Guo, Liangyu Zhang, Hu Tang, Peiwen Liu, Bin Hu, Yue Gong, Rui Hou, Ziheng Wu   +7 more
wiley   +1 more source

Immunotherapy in gastric cancer-A systematic review. [PDF]

Oncol Res
Santos M, Martins D, Mendes F.
europepmc   +1 more source